Ideos Unidia is commonly used to help with the symptomatic management of conditions presenting with systemic or localized discomfort related to deficiencies in calcium and Vitamin D. The medicine is applied in addressing symptoms related to systemic imbalance of Vitamin D and calcium, particularly in older adults.

The product is relevant for supporting patients experiencing symptoms related to systemic imbalance due to combined Vitamin D and calcium deficiencies, and acting as an adjunct to established treatments for osteoporosis. The product is considered relevant when supportive symptom management is appropriate in these clinical scenarios. It is applied in scenarios where additional management of discomfort is required to assist patients during difficult episodes.

The combined formulation contributes to easing the overall symptom load by assisting with maintaining functional stability, which is often affected by the underlying deficiency. This therapeutic approach may assist with addressing symptom clusters that create noticeable functional strain related to systemic imbalance. It is often used during phases when symptoms become more noticeable and may be part of symptomatic management to support general well-being during symptomatic phases.

Quick Fact: Relief for Systemic Imbalance

Regulatory References

1. Spanish Agency of Medicines and Health Products (CIMA)

Who Can and Cannot Use Ideos Unidia?

The population eligibility for Ideos Unidia is strictly governed by regulatory authorities, focusing on conditions that affect calcium and Vitamin D homeostasis.

Contraindications (Who Must Not Use It)

Ideos Unidia is absolutely prohibited in patients with pre-existing elevated mineral levels, specific organ dysfunction, or hypersensitivity:

• Mineral Status: Patients with hypercalcaemia, hypercalciuria, or hypervitaminosis D.
• Organ/Stone Disease: Patients with severe renal impairment or a history of calcium lithiasis (kidney stones).
• Comorbid Conditions: Individuals with diseases causing high blood calcium, such as myeloma or primary hyperparathyroidism.
• Allergies: Known hypersensitivity to the active substances or excipients (e.g., peanut/soya allergy).

---

Population and Conditional Restrictions

Category	Regulatory Status
Age Group	Adults are the approved population; use is not intended for children and adolescents.
Renal Function	Mild to moderate renal impairment requires caution and monitoring of calcium levels.
Pregnancy/Lactation	Use is permissible but conditional; intake must not exceed specified maximum daily doses.
Metabolic/Genetic	Contraindicated in rare hereditary conditions such as fructose intolerance due to excipient content.

These rules ensure the medicine is only used by populations whose eligibility is established and whose risk of toxicity is minimized.

The interaction profile for Ideos Unidia (Calcium Carbonate and Dihydrotachysterol) is defined by two primary regulatory constraints: the risk of additive effects on calcium levels and the potential for the calcium component to interfere with the absorption of other medicines.

High-Risk and Additive Combinations

Co-administration with other sources of calcium or Vitamin D is strictly documented as contraindicated without intensive medical supervision due to the significant risk of hypercalcaemia (elevated calcium). Similarly, the combination with Cardiac Glycosides (like Digoxin) or Thiazide Diuretics is classified as high-risk, as hypercalcaemia may increase toxicity or reduce renal calcium excretion.

Mandatory Timing-Based Separation

To prevent the calcium component from reducing the systemic exposure of other medicines, official labeling requires mandatory separation periods.

Interacting Substance/Class	Minimum Separation Requirement (hours)	Official Outcome
Quinolone/Tetracycline Antibiotics	2 to 6 hours apart	Reduced antibiotic absorption
Thyroid Hormones (Levothyroxine)	At least 4 hours apart	Reduced hormone absorption
Iron or Zinc Salts, Estramustine	At least 2 hours apart	Reduced medicinal product absorption
HIV Integrase Inhibitors	2 hours after or 6 hours before calcium	Reduced inhibitor absorption

Metabolic and Food Interactions

The therapeutic effect of the Dihydrotachysterol component may be officially decreased by co-administration with enzyme-inducing medicinal products, such as Phenytoin or Rifampicin. Furthermore, the absorption of Ideos Unidia is reduced when taken with foods containing Oxalic Acid (e.g., spinach) or Phytic Acid (e.g., whole cereals), requiring administration to be separated from these meals. Monitoring of calcium levels is particularly important in elderly patients co-treated with Diuretics.

How Ideos Unidia Works

The action of Ideos Unidia is rooted in the complementary pharmacodynamic mechanisms of its two active components, Calcium Carbonate and Dihydrotachysterol, which together modulate the body's mineral homeostasis axis.

The synthetic component, Dihydrotachysterol, operates by acting as an agonist at the Vitamin D Receptor (VDR), a nuclear receptor that regulates gene expression in intestinal and renal cells. This molecular interaction initiates a mechanistic cascade involving the upregulation of genes responsible for key transport proteins, such as Calbindin mathbfD9k, thereby increasing the capacity for intestinal epithelial transport.

The second component, Calcium Carbonate, provides the elemental mathbfCa^2+ substrate, which is utilized by the transport mechanisms enhanced by VDR agonism. This substrate-stimulus complementarity drives the Intestinal Calcium Absorption Pathway and supports the Renal Calcium Reabsorption Pathway, which is a central mechanistic step in regulating systemic mineral levels.

The net physiological effect of this mechanism is the sustained modulation of plasma mathbfCa^2+ concentrations. By influencing systemic mineral balance, the mechanism modulates the electrical potential of nerve and muscle cell membranes, which is central to neuromuscular excitability and influences mineral availability for skeletal structure.

How Ideos Unidia is Used

The administration of Ideos Unidia (Calcium Carbonate 500 mg / Cholecalciferol 400 IU) consists of an oral regimen. As a combination product, its use is structured to support appropriate mineral and Vitamin D intake and is limited to specific patient groups.

Oral Administration and Dosing

The medicine is designed for oral use only. The standard adult dosing regimen requires the ingestion of one tablet twice a day, resulting in a total daily dose of 1000 mg elemental calcium and 800 IU Cholecalciferol.

Administration Principle	Usage Specification
Route of Administration	Oral use (ingestion)
Standard Adult Dose	One tablet, twice daily (Total 1000 mg Calcium / 800 IU Cholecalciferol)
Administration Technique	The tablet must be fully chewed or sucked before swallowing, often followed by a glass of water

The timing of use includes a restriction: the medicine should be taken at least two hours apart from meals containing high amounts of calcium absorption inhibitors, such as oxalic or phytic acids (e.g., spinach and whole cereals). If a dose is forgotten, a double dose must not be taken to compensate.

Contextual and Duration-Based Usage

The usage protocol is generally intended for long-term treatment to support mineral homeostasis. Continued long-term use involves the periodic monitoring of serum and urinary calcium levels and kidney function. Furthermore, the standard regimen is specified for adults only, with no relevant use outlined for the pediatric population. The daily intake for pregnant or lactating women is restricted to a maximum of one tablet.

Research evidence / Overview of studies for Ideos Unidia

This section summarizes the official research that has been conducted on the combination of Calcium Carbonate and Dihydrotachysterol, detailing the study types examined and areas of uncertainty, without offering clinical advice.

---

Evidence for Managing Combined Mineral Deficiencies

Research has explored the use of this combination for individuals presenting with low calcium and Vitamin D levels. Clinical investigations and observational reports have focused on documenting how the combination was evaluated in deficient populations. Studies primarily monitored outcomes related to systemic imbalance by measuring shifts in biomarkers, such as serum calcium. Findings describe patterns observed in the research related to the shift of low calcium levels. What remains uncertain is that large-scale, prospective randomized controlled trials (RCTs) specifically utilizing the Dihydrotachysterol combination for general deficiency management are not as numerous as those for other common Vitamin D forms.

---

Evidence for Adjunctive Support in Osteoporosis

The use of the combination was studied for its evaluation alongside established treatments for osteoporosis, particularly in older adults and postmenopausal women. The evidence landscape includes RCTs and systematic reviews that research examined using combination Vitamin D and calcium therapy. Studies monitored outcomes related to bone structural integrity and function, including Bone Mineral Density (BMD) and fracture incidence rates. The certainty remains low regarding the direct comparative assessment of this specific Dihydrotachysterol combination versus other common regimens in fracture studies, and results apply only to the specific populations studied.

---

Evidence in Specialized Patient Groups and Research Gaps

Research has explored the use of the active components in specialized populations, including patients with certain forms of hypoparathyroidism and individuals with impaired renal function. These studies are typically small-scale, controlled clinical studies that examined the effect on plasma calcium and phosphate concentrations in these complex settings. Extrapolation is limited due to the small sample sizes.

A consistent pattern is that certainty remains low in several areas: comparative evidence is lacking for the Dihydrotachysterol combination versus more commonly used Vitamin D/calcium regimens. Clinical trials for deficiency management are often of short-term duration, and long-term effects are not fully established for the sustained maintenance of calcium balance over many years.

Key Studies & References

1. Prospecto: Ideos (Calcium Carbonate and Dihydrotachysterol) - Regulatory Product Information
2. Calcium and vitamin D supplementation for preventing fractures in postmenopausal women: a meta-analysis

Common questions about Ideos Unidia (FAQ)

Q: Can I take Ideos Unidia on an empty stomach?

A: Official information requires specific administration conditions, such as separating the medicine by at least two hours from meals containing high amounts of calcium absorption inhibitors (like spinach or whole cereals). Regulatory documents do not contain general instructions specifying whether the medicine must be taken with or without food.

Q: What is the difference between Dihydrotachysterol and regular Vitamin D?

A: According to official product information, Dihydrotachysterol is classified as a synthetic analogue of Vitamin D. This means it is a manufactured substance chemically similar to, but distinct from, natural Vitamin D. Its action at the Vitamin D Receptor (VDR) is the basis for how it is believed to influence the body's mineral levels.

Q: Where should I dispose of expired Ideos Unidia?

A: Official regulatory instructions mandate that this medicine and its packaging must not be discarded in regular household waste or poured down the drain. To assist with environmental protection, the medicine is to be returned by depositing it at a designated pharmaceutical collection point, such as a local pharmacy’s collection service.

Q: Does Ideos Unidia contain lactose or gluten?

A: Official regulatory documents, such as the Summary of Product Characteristics (SmPC) or FDA Label, include a full list of all inactive ingredients, which are also known as excipients. This list details whether specific substances like lactose or gluten-containing compounds are present in the final formulation. The detailed list of excipients in the product documentation is the resource for confirming the presence of these compounds.

Q: What should I do if I suspect an overdose?

A: The official product information addresses the potential for an overdose, which is typically linked to a condition called hypercalcaemia (abnormally high blood calcium). The documentation specifies the symptoms associated with an overdose and outlines the medical management and necessary interventions for this condition.

Storage and Disposal Requirements

Ideos Unidia must be stored and disposed of strictly according to the conditions mandated in the official regulatory product information.

Requirement Category	Official Instruction
Maximum Temperature	Do not store above 25 C
Child Protection	Keep out of the sight and reach of children
Stability Limit	Do not use after the labeled expiration date (CAD)

To comply with the regulatory mandate to maintain product stability, the medicine must not be exposed to temperatures exceeding 25 C. For safety, the product must be kept inaccessible to children. Expired or unused Ideos Unidia must not be thrown away in household waste or wastewater. Instead, the medication and packaging must be deposited at a designated pharmaceutical collection point (e.g., a pharmacy’s SIGRE Point) to assist with environmental protection.